4.7 Review

Advances in the development paradigm of biosample-based biosensors for early ultrasensitive detection of alzheimer's disease

期刊

JOURNAL OF NANOBIOTECHNOLOGY
卷 19, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12951-021-00814-7

关键词

Alzheimer's disease; Biosample; Biomarker; Biosensor; Early detection

资金

  1. National Research Foundation of Korea - Ministry of Science and ICT [NRF-2020R1A4A2002817, 2018R1D1A3B07047434, 2019R1I1A3A01060695]
  2. National Research Foundation of Korea [2018R1D1A3B07047434, 2019R1I1A3A01060695] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

This review discusses the current progress, challenges, and future directions of using invasive and noninvasive biosample-based small biosensors for early diagnosis of Alzheimer's disease with specific biomarkers. Various detection scales, biosamples, sensor types, and analyzing techniques for ultrasensitive detection of AD biomarkers are highlighted, along with future trends in enhancing sensor sensitivity and discovering new biomarker types using non-invasive body fluids.
This review highlights current developments, challenges, and future directions for the use of invasive and noninvasive biosample-based small biosensors for early diagnosis of Alzheimer's disease (AD) with biomarkers to incite a conceptual idea from a broad number of readers in this field. We provide the most promising concept about biosensors on the basis of detection scale (from femto to micro) using invasive and noninvasive biosamples such as cerebrospinal fluid (CSF), blood, urine, sweat, and tear. It also summarizes sensor types and detailed analyzing techniques for ultrasensitive detection of multiple target biomarkers (i.e., amyloid beta (A beta) peptide, tau protein, Acetylcholine (Ach), microRNA137, etc.) of AD in terms of detection ranges and limit of detections (LODs). As the most significant disadvantage of CSF and blood-based detection of AD is associated with the invasiveness of sample collection which limits future strategy with home-based early screening of AD, we extensively reviewed the future trend of new noninvasive detection techniques (such as optical screening and bio-imaging process). To overcome the limitation of non-invasive biosamples with low concentrations of AD biomarkers, current efforts to enhance the sensitivity of biosensors and discover new types of biomarkers using non-invasive body fluids are presented. We also introduced future trends facing an infection point in early diagnosis of AD with simultaneous emergence of addressable innovative technologies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据